Log In
Print
BCIQ
Print
Print this Print this
 

Cometriq, cabozantinib (XL184)

  Manage Alerts
Collapse Summary General Information
Company Exelixis Inc.
DescriptionSpectrum-selective kinase inhibitor of VEGF receptor 2 (KDR/Flk-1; VEGFR-2) and c-Met receptor tyrosine kinase
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2) ; c-Met receptor tyrosine kinase
Mechanism of ActionVascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) kinase inhibitor; MET inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today